Core Team

Imago has an experienced management team, leading advisors in MPNs and hematologic malignancies, and well-known life science investors including Blackstone Life Sciences, Frazier Healthcare Partners and Omega Funds with several corporate investors participating.

The team is led by Hugh Young Rienhoff, Jr., a physician with 25 years of experience in the field of biotechnology. The operational team provides broad oversight of clinical trials, quality and chemical manufacturing. Imago’s operational model facilitates the team’s management of CMC activities and clinical studies in Europe, Asia and North America in multiple therapeutic areas, notably hematology and oncology. Imago has established many collaborations with clinical investigators and scientists to continuously enhance the scientific foundation of our clinical programs.

Imago is developing pioneering medicines for the treatment of myeloproliferative diseases.

THE PROMISE OF IMAGO

Management

Hugh Y. Rienhoff, Jr. M.D.

Hugh Y. Rienhoff, Jr. M.D.

Chief Executive Officer

Laura G. Eichorn

Laura G. Eichorn

Chief Operating Officer

Jennifer Peppe

Jennifer Peppe

Senior Vice President

Amy E. Tapper, PhD

Amy E. Tapper, Ph.D.

Senior Vice President